Jeroen Bastiaans, PhD
About Jeroen Bastiaans, PhD
Jeroen Bastiaans, PhD, is a Senior Scientist at MeiraGTx, where he leads the neuroprotection program and collaborates on ocular projects. He has a strong background in Biological and Biomedical Sciences, with extensive experience in research roles at prestigious institutions.
Work at MeiraGTx
Jeroen Bastiaans serves as a Senior Scientist at MeiraGTx, a position he has held since 2022. In this role, he leads the neuroprotection program, where he manages and executes experiments while supervising a team of research associates. He collaborates with external parties and supports ocular projects run by MeiraGTx's London-based teams. His work focuses on advancing gene therapies, particularly through the design and analysis of synthetic tissue-specific and constitutive promoters for AAV-based applications.
Education and Expertise
Jeroen Bastiaans earned a Doctor of Philosophy (PhD) in Biological and Biomedical Sciences from Erasmus University Rotterdam, completing his studies from 2011 to 2015. He also holds a Bachelor's degree in Biotechnology from HAN University of Applied Sciences, which he obtained from 2001 to 2004. His educational background provides a strong foundation in biological sciences, which is reflected in his research and professional endeavors in the field of gene therapy and neuroprotection.
Background
Prior to his current role at MeiraGTx, Jeroen Bastiaans held several significant positions in research institutions. He worked as a Postdoctoral Research Scientist at Columbia University Medical Center in the Department of Ophthalmology from 2016 to 2018, and later at Weill Cornell Medicine from 2018 to 2022. He began his research career as a PhD Candidate at Erasmus MC from 2011 to 2015 and also worked as a Research Technician at The Rotterdam Eye Hospital from 2009 to 2011. Additionally, he served as President of the Columbia University Postdoctoral Society from 2017 to 2018.
Research Contributions
Jeroen Bastiaans has made significant contributions to the field of gene therapy and neuroscience. His research involves developing in vivo and in vitro models to study central nervous system-specific therapies, utilizing surgical injection techniques and induced pluripotent stem cell (iPSC)-derived neural models. He also contributes to the design and analysis of synthetic promoters for adeno-associated virus (AAV)-based gene therapies, which are critical for advancing therapeutic options in ocular and CNS disorders.